Analysts Set Johnson & Johnson (NYSE:JNJ) Target Price at $189.78

Johnson & Johnson (NYSE:JNJGet Rating) has been given an average rating of “Moderate Buy” by the twelve brokerages that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $189.78.

JNJ has been the subject of several research reports. Citigroup cut their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. UBS Group cut their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. Morgan Stanley lowered their price objective on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Monday, September 12th. Finally, SVB Leerink lowered their price objective on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th.

Johnson & Johnson Trading Down 1.0 %

NYSE JNJ opened at $163.28 on Thursday. The company has a market cap of $429.29 billion, a PE ratio of 23.77, a PEG ratio of 2.97 and a beta of 0.61. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The stock has a 50 day moving average of $168.25 and a 200-day moving average of $174.16.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter last year, the firm posted $2.48 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 10.7 EPS for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has approved a share buyback program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Family CFO Inc acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $26,000. RE Dickinson Investment Advisors LLC boosted its stake in Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after buying an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC boosted its stake in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after buying an additional 120 shares in the last quarter. Morton Brown Family Wealth LLC boosted its stake in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after buying an additional 78 shares in the last quarter. Finally, Professional Financial Advisors LLC boosted its stake in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after buying an additional 68 shares in the last quarter. Institutional investors own 68.59% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.